Repertoire Immune Medicines, a biotechnology company, has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. Under the terms of the agreement, Repertoire will lead target discovery activities using its DECODE platform to explore a large antigenic space, and Genentech will be responsible for preclinical and clinical development as well as the global c...